MD&A Guidance and a New Landscape for Confidential Treatment
Morrison & Foerster’s Dave Lynn and Marty Dunn provide a brief update about the U.S. Securities and Exchange Commission’s recent MD&A interpretive release regarding key performance indicators and metrics disclosures, as well as the changes in practice for seeking confidential treatment of information filed with the SEC.
Disclaimer
Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.
